Shopping Cart
- Remove All
Your shopping cart is currently empty
Patecibart
Catalog No. T81538Cas No. 2642374-04-5
Patecibart, a humanized immunoglobulin G4-kappa monoclonal antibody, acts as an antagonist to the endothelin receptor A (EDNRA).
Patecibart
Patecibart
Catalog No. T81538Cas No. 2642374-04-5
Patecibart, a humanized immunoglobulin G4-kappa monoclonal antibody, acts as an antagonist to the endothelin receptor A (EDNRA).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | Backorder | |
| 5 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Patecibart"
Ambrisentan
LU 208075, BSF-208075, BSF 208075
T1655177036-94-1
Ambrisentan (BSF 208075) is an endothelin receptor antagonist used in the therapy of pulmonary arterial hypertension (PAH). Ambrisentan has been associated with a low rate of serum enzyme elevations during therapy but has yet to be implicated in cases of clinically apparent acute liver injury.
- $30
Size
QTY
Bosentan
Cited
Ro 47-0203, Benzenesulfonamide, Actelion
T6264147536-97-8
Bosentan (Benzenesulfonamide) is a sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan decreases both pulmonary and systemic vascular resistance and is particularly used in the treatment of pulmonary arterial hypertension.
- $32
Size
QTY
CitedSparsentan
RE-021, DARA-a
T5355254740-64-2
Sparsentan (DARA-a) is a first-in-class orally active and highly potent dual endothelin A and angiotensin II receptor antagonist(Ki of 9.3 and 0.8 nM, respectively)
- $33
Size
QTY
BMS 182874 hydrochloride
T217901215703-04-0
BMS 182874 hydrochloride is a nonpeptide endothelin (El) receptor antagonist.
- $74
Size
QTY
Aprocitentan
ACT-132577
T78171103522-45-7
Aprocitentan (ACT-132577) is ETA and ETB antagonist .
- $53
Size
QTY
Sulfisoxazole
Sulfafurazole, NU-445
T0750127-69-5
Sulfisoxazole (Sulfafurazole) is a short-acting sulfonamide antibacterial with activity against a wide range of gram-negative and gram-positive organisms.Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A.
- $31
Size
QTY
Macitentan
ACT-064992
T2561441798-33-0
Macitentan (ACT-064992) is an endothelin receptor antagonist utilized in the treatment of pulmonary arterial hypertension (PAH).
- $37
Size
QTY
Clazosentan
VML 588, Ro 61-1790, AXV-034343
T64084180384-56-9In house
Clazosentan (Ro 61-1790) is a selective antagonist of the endothelin A receptor (ETAreceptor) that inhibits ET-1-mediated vasoconstriction, preventing cerebral vasospasm and vasospasm-associated cerebral infarction.
- $84
Size
QTY
Sitaxsentan sodium
Thelin, TBC11251 sodium salt, TBC11251, Sitaxentan sodium
T6672210421-74-2
Sitaxsentan sodium (TBC11251 sodium salt) is a highly selective antagonist of endothelin A receptors.
- $30
Size
QTY
BMS 182874
BMS-182874, BMS182874
T26841153042-42-3
BMS 182874 is an orally effective and highly selective endothelin receptor ETA antagonist with an IC50 value of 0.150 μM for ETA and a Ki value of 0.055 μM for ETA.BMS 182874 is able to reduce arterial pressure in a rat hypertension model induced by Deoxycorticosterone acetate. BMS 182874 was able to reduce Deoxycorticosterone-induced arterial pressure in a rat model of hypertension and can be used to study cardiovascular disease.
- $68
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Patecibart, a humanized immunoglobulin G4-kappa monoclonal antibody, acts as an antagonist to the endothelin receptor A (EDNRA). |
| Cas No. | 2642374-04-5 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Patecibart | purchase Patecibart | Patecibart cost | order Patecibart
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.